INBX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-2.080

-53.47%

-1.210

-56.79%

-1.120

-39.46%

Estimates Revision

The market is revising No Change the revenue expectations for Inhibrx, Inc. (INBX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 124.43%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+124.43%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Inhibrx Biosciences Inc (INBX.O) is -13.38, compared to its 5-year average forward P/E of -2.80. For a more detailed relative valuation and DCF analysis to assess Inhibrx Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.80

Current PE

-13.38

Overvalued PE

1.69

Undervalued PE

-7.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.29

Current PS

0.00

Overvalued PS

42.18

Undervalued PS

-31.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INBX News & Events

Events Timeline

No data

News

9.5

2025-12-31NASDAQ.COM

Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments

2.0

2025-12-24Benzinga

Inhibrx Stock Surges 150% Post Ozekibart Trial Results but Faces Structural Risks

9.0

2025-12-17NASDAQ.COM

Inhibrx Progresses with INBRX-106 and Ozekibart Programs, Anticipates Major Milestones in the Coming Year

People Also Watch

Frequently Asked Questions

What is Inhibrx Biosciences Inc (INBX) stock price today?

The current price of INBX is 72.86 USD — it has decreased -3.11 % in the last trading day.

What is Inhibrx Biosciences Inc (INBX)'s business?

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

What is the price predicton of INBX Stock?

Wall Street analysts forecast INBX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Inhibrx Biosciences Inc (INBX)'s revenue for the last quarter?

Inhibrx Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Inhibrx Biosciences Inc (INBX)'s earnings per share (EPS) for the last quarter?

Inhibrx Biosciences Inc. EPS for the last quarter amounts to -2.28 USD, decreased -19.72 % YoY.

What changes have occurred in the market's expectations for Inhibrx Biosciences Inc (INBX)'s fundamentals?

How many employees does Inhibrx Biosciences Inc (INBX). have?

Inhibrx Biosciences Inc (INBX) has 156 emplpoyees as of January 10 2026.

What is Inhibrx Biosciences Inc (INBX) market cap?

Today INBX has the market capitalization of 1.06B USD.